nach oben

Die Gastroenterologie

Erschienen in:

08.12.2023 | Reizdarmsyndrom | CME

Funktionelle Magen-Darm-Erkrankungen

Diagnostische Herausforderungen und evidenzbasierte Therapieansätze

verfasst von: PD Dr. Jutta Keller, Prof. Dr. Arne Kandulski

Erschienen in: Die Gastroenterologie | Ausgabe 6/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Funktionelle Magen-Darm-Erkrankungen („functional gastrointestinal disorders“, FGID) stellen eine Herausforderung im Bereich der Gastroenterologie dar. Reizdarmsyndrom („irritable bowel syndrome“, IBS) und funktionelle Dyspepsie (FD) sind die bedeutsamsten funktionellen Störungen im Spektrum der chronischen funktionellen Magen-Darm-Erkrankungen. FGID werden als Störungen der Darm-Hirn-(Mikrobiom)-Achse („disorders of gut brain interaction“, DGBI) definiert. Die aktualisierte S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) für das Reizdarmsyndrom bietet einen pragmatischen Ansatz für die klinische Praxis zur Diagnose und symptombasierenden Behandlung funktioneller Magen-Darm-Erkrankungen. Die S3-Leitlinie berücksichtigt die pathophysiologischen Mechanismen und integriert diese in die Behandlungskonzepte, die stets als individuelle Therapiepläne verstanden werden sollten. Sie umfassen ernährungstherapeutische Methoden, psychoedukative Möglichkeiten sowie komplementäre medizinische Ansätze, einschließlich Phytotherapeutika und Probiotika zusammen mit herkömmlichen pharmakologischen Wirkstoffen. Das Ziel des Behandlungskonzepts für funktionelle Magen-Darm-Erkrankungen besteht darin, Symptome zu lindern und die Lebensqualität der Patient*innen zu verbessern.

Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J et al (2016) Gastroduodenal disorders. Gastroenterology 150:1380–1392PubMed

Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M et al (2016) Bowel disorders. Gastroenterology 150:1393–1407.e5

Fairlie T, Shah A, Talley NJ, Chey WD, Koloski N, Yeh Lee Y et al (2023) Overlap of disorders of gut-brain interaction: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8:646–659PubMed

Hunt RH, Tougas G (2002) Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments. Baillieres Best Pract Res Clin Gastroenterol 16:869–883

Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S et al (2021) Update S3-Leitlinie Reizdarmsyndrom: definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016. Z Gastroenterol 59:1323–1415PubMed

Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491PubMed

Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920–924PubMed

Haag S, Andrews JM, Gapasin J, Gerken G, Keller A, Holtmann GJ et al A 13-nation population survey of upper gastrointestinal symptoms: prevalence of symptoms and socioeconomic factors. https://doi.org/10.1111/j.1365-2036.2010.04564.x

Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M (2020) Prevalence of rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology 158:1262–1273.e3PubMed

10.

Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al (2021) Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterology 160:99–114.e3PubMed

11.

Lovell RM, Ford AC (2012) Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 107:991–1000PubMed

12.

Lacy BE, Cangemi D, Vazquez-Roque M (2021) Management of chronic abdominal distension and bloating. Clin Gastroenterol Hepatol 19:219–231.e1PubMed

13.

Barbara G, Feinle-Bisset C, Ghoshal UC, Santos J, Vanner SJ, Vergnolle N et al (2016) The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology 150:1305–1318.e8

14.

Black CJ, Ford AC (2020) Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 17:473–486PubMed

15.

Van Oudenhove L, Levy RL, Crowell MD, Drossman DA, Halpert AD, Keefer L et al (2016) Biopsychosocial aspects of functional gastrointestinal disorders. Gastroenterology 150:1355–1367.e2

16.

Spiller R, Garsed K (2009) Postinfectious irritable bowel syndrome. Gastroenterology 136:1979–1988PubMed

17.

Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M et al (2017) Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 152:1042–1054.e1PubMed

18.

Donnachie E, Schneider A, Mehring M, Enck P (2018) Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut 67:1078–1086PubMed

19.

Tack J, Schol J, Van den Houte K, Huang IH, Carbone F (2021) Paradigm shift: functional dyspepsia‑A „leaky gut“ disorder? Am J Gastroenterol 116:274–275PubMed

20.

Holtmann G, Shah A, Morrison M (2017) Pathophysiology of functional gastrointestinal disorders: a holistic overview. Dig Dis 35(Suppl 1):5–13PubMed

21.

Broeders BWLCM, Carbone F, Balsiger LM, Schol J, Raymenants K, Huang I et al (2023) Review article: functional dyspepsia‑a gastric disorder, a duodenal disorder or a combination of both? Aliment Pharmacol Ther 57:851–860PubMed

22.

Park SY, Acosta A, Camilleri M, Burton D, Harmsen WS, Fox J et al (2017) Gastric motor dysfunction in patients with functional gastroduodenal symptoms. Am J Gastroenterol 112:1689–1699PubMed

23.

Simrén M, Törnblom H, Palsson OS, Van Tilburg MAL, Van Oudenhove L, Tack J et al (2018) Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut 67:255–262PubMed

24.

Pinto-Sanchez MI, Ford AC, Avila CA, Verdu EF, Collins SM, Morgan D et al (2015) Anxiety and depression increase in a stepwise manner in parallel with multiple FGIDs and symptom severity and frequency. Am J Gastroenterol 110:1038–1048PubMed

25.

Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ (2020) Functional dyspepsia. Lancet 396:1689–1702PubMed

26.

Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P et al (2021) United European gastroenterology (UEG) and European society for neurogastroenterology and motility (ESNM) consensus on functional dyspepsia. Neurogastroenterol Motil. https://doi.org/10.1111/NMO.14238 (33)CrossRefPubMed

27.

Whitehead WE, Winget C, Fedoravicius AS, Wooley S, Blackwell B (1982) Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 27:202–208PubMed

28.

Schumann D, Anheyer D, Lauche R, Dobos G, Langhorst J, Cramer H (2016) Effect of yoga in the therapy of irritable bowel syndrome: a systematic review. Clin Gastroenterol Hepatol 14:1720–1731PubMed

29.

Evans S, Lung KC, Seidman LC, Sternlieb B, Zeltzer LK, Tsao JCI (2014) Iyengar yoga for adolescents and young adults with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 59:244–253PubMedPubMedCentral

30.

Reese I, Ballmer-Weber B, Beyer K, Dölle-Bierke S, Kleine-Tebbe J, Klimek L et al (2021) Guideline on management of suspected adverse reactions to ingested histamine: guideline of the German society for allergology and clinical immunology (DGAKI), the society for pediatric allergology and environmental medicine (GPA), the medical association of German allergologists (AeDA) as well as the Swiss society for allergology and immunology (SGAI) and the Austrian society for allergology and immunology (ÖGAI). Allergol Sel 5:305–314

31.

Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ (2015) Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther 41:844–855PubMed

32.

Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR et al (2014) Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. https://doi.org/10.1038/AJG.2014.148 (109)CrossRefPubMed

33.

Krouwel M, Farley A, Greenfield S, Ismail T, Jolly K (2021) Systematic review, meta-analysis with subgroup analysis of hypnotherapy for irritable bowel syndrome, effect of intervention characteristics. Complement Ther Med. https://doi.org/10.1016/J.CTIM.2021.102672 (57)CrossRefPubMed

34.

Wiles NJ, Thomas L, Turner N, Garfield K, Kounali D, Campbell J et al (2016) Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the coBalT randomised controlled trial. Lancet Psychiatry 3:137–144PubMed

35.

Everitt HA, Landau S, O’Reilly G, Sibelli A, Hughes S, Windgassen S et al (2019) Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial. Lancet Gastroenterol Hepatol 4:863–872PubMedPubMedCentral

36.

Camilleri M, Ford AC (2017) Pharmacotherapy for Irritable bowel syndrome. J Clin Med. https://doi.org/10.3390/JCM6110101CrossRefPubMedPubMedCentral

37.

Ford AC, Moayyedi P, Black CJ, Yuan Y, Veettil SK, Mahadeva S et al (2021) Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther 53:8–21PubMed

38.

Talley NJ, Richard Locke G, Saito YA, Almazar AE, Bouras EP, Howden CW et al (2015) Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology 149:340–349.e2PubMed

39.

Tack J, Ly HG, Carbone F, Vanheel H, Vanuytsel T, Holvoet L et al (2016) Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol 14:385–392.e4PubMed

40.

Lewis-Fernández R, Lam P, Lucak S, Galfalvy H, Jackson E, Fried J et al (2016) An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder. J Clin Psychopharmacol 36:710–715PubMed

41.

Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG, Hudson JI (2009) Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 24:423–428PubMed

42.

Khanna R, Macdonald JK, Levesque BG (2014) Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 48:505–512PubMed

43.

Cash BD, Epstein MS, Shah SM (2016) A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci 61:560–571PubMed

44.

Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R (2010) The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 55:1385–1390PubMed

45.

Lauche R, Janzen A, Lüdtke R, Cramer H, Dobos G, Langhorst J (2015) Efficacy of caraway oil poultices in treating irritable bowel syndrome—a randomized controlled cross-over trial. Digestion 92:22–31PubMed

46.

Madisch A, Frieling T, Zimmermann A, Hollenz M, Labenz J, Stracke B et al (2023) Menthacarin, a proprietary peppermint oil and caraway oil combination, improves multiple complaints in patients with functional gastrointestinal disorders: a systematic review and meta-analysis. Dig Dis 41:522–532PubMed

47.

Chen C, Tao C, Liu Z, Lu M, Pan Q, Zheng L et al (2015) A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res 29:1822–1827PubMed

48.

Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M (2002) A novel treatment for constipation-predominant irritable bowel syndrome using padma lax, a tibetan herbal formula. Digestion 65:161–171PubMed

49.

Madisch A, Holtmann G, Plein K, Hotz J (2004) Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19:271–279PubMed

50.

Von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P (2007) STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 102:1268–1275

51.

Báez G, Vargas C, Arancibia M, Papuzinski C, Franco JVA (2023) Non-Chinese herbal medicines for functional dyspepsia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013323.PUB2 (6)CrossRefPubMed

52.

Corazziari ES, Gasbarrini A, D’Alba L, D’Ovidio V, Riggio O, Passaretti S et al (2023) Poliprotect vs omeprazole in the relief of heartburn, epigastric pain, and burning in patients without erosive esophagitis and gastroduodenal lesions: a randomized, controlled trial. Am J Gastroenterol. https://doi.org/10.14309/ajg.0000000000002360CrossRefPubMedPubMedCentral

53.

Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P (2018) Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 48:1044–1060PubMed

54.

Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ et al (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325–332PubMed

55.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J et al (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364:22–32PubMed

56.

Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB et al (2016) Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 151:1113–1121PubMed

57.

Wauters L, Slaets H, De Paepe K, Ceulemans M, Wetzels S, Geboers K et al (2021) Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 6:784–792PubMed

58.

Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW (2011) Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003460.PUB3 (2011)CrossRefPubMedPubMedCentral

59.

Saito YA, Almazar AE, Tilkes KE, Choung RS, Van Norstrand MD, Schleck CD et al (2019) Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 49:389–397PubMedPubMedCentral

60.

Chapman RW, Stanghellini V, Geraint M, Halphen M (2013) Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 108:1508–1515PubMed

61.

Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R (2014) Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 26:21–27PubMed

62.

Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y (2014) Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil 26:499–509PubMed

63.

Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M (2008) Effects of 5‑hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 6:545–555PubMedPubMedCentral

64.

Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G et al (2014) A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63:1617–1625PubMed

65.

Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C et al (2022) Management of helicobacter pylori infection: the Maastricht VI/florence consensus report. Gut 71:1724–1762

66.

- (2023) Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Juli 2022 – AWMF-Registernummer: 021–001. Z Gastroenterol 61:544–606PubMed

67.

Wauters L, Ceulemans M, Frings D, Lambaerts M, Accarie A, Toth J et al (2021) Proton pump inhibitors reduce duodenal eosinophilia, mast cells, and permeability in patients with functional dyspepsia. Gastroenterology 160:1521–1531.e9PubMed

68.

Peura DA, Kovacs TOG, Metz DC, Siepman N, Pilmer BL, Talley NJ (2004) Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 116:740–748PubMed

69.

Sakaguchi M, Takao M, Ohyama Y, Oka H, Yamashita H, Fukuchi T et al (2012) Comparison of PPis and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. World J Gastroenterol 18:1517–1524PubMedPubMedCentral

70.

Rich G, Shah A, Koloski N, Funk P, Stracke B, Köhler S et al (2017) A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol Motil. https://doi.org/10.1111/NMO.13132 (29)CrossRefPubMed

71.

Madisch A, Heydenreich CJ, Wieland V, Hufnagel R, Hotz J (1999) Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride: a multicenter, reference-controlled double-blind equivalence study. Arzneimittel-forschung/drug Res 49:925–932

72.

Holtmann G, Haag S, Adam B, Funk P, Wieland V, Heydenreich CJ (2003) Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia. Phytomedicine 10(Suppl 4):56–57PubMed

Titel: Funktionelle Magen-Darm-Erkrankungen
Diagnostische Herausforderungen und evidenzbasierte Therapieansätze
verfasst von: PD Dr. Jutta Keller
Prof. Dr. Arne Kandulski
Publikationsdatum: 08.12.2023
Verlag: Springer Medizin
Schlagwörter: Reizdarmsyndrom
Phytotherapie
Darmmikrobiom
Erschienen in: Die Gastroenterologie / Ausgabe 6/2023
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-023-00734-y

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Chronisch entzündliche Darmerkrankungen

Mitteilungen des Verein Netzwerk gegen Darmkrebs e. V.

Mitteilungen des BDI

Prädiktion von Krankheitsverlauf und Therapieerfolg

Mitteilungen der Stiftung LebensBlicke

Kompetenzerwerb im Management als Grundlage für Mitgestaltung in einer medizinischen Welt des stetigen Wandels

Magen-Darm-Erkrankungen in der Hausarztpraxis